Will vosoritide be included in medical insurance and cost explanation in China?

Vorasotide (trade name Vosoritide) is a targeted treatment drug for children with achondroplasia (achondroplasia). It mainly activates bone growth-related signaling pathways to promote chondrocyte differentiation and bone elongation, thereby improving the height development of children. The drug has shown good efficacy in clinical trials and is especially suitable for growing children. However, it has not yet been officially launched in China, so domestic patients cannot directly obtain the drug for the time being.

Since Vorsolitide has not yet been marketed in China, it is naturally not included in the national medical insurance reimbursement system. At present, domestic patients can only pay attention to overseas versions of drug purchase channels, but these channels involve cross-border drug purchase and import procedures, making it difficult to obtain. Medical insurance policies usually target drugs that have been officially marketed and approved, so it still takes time and policy support to include vorsolitide in medical insurance in China.

In terms of price, the price of the original vorsoritide drug listed overseas is relatively high. Taking the European market as an example, the price of each box of drugs is approximately 69,000 yuan. This price reflects the high cost of drug research and development, special indications, and narrow market positioning. There are currently no generic drugs available, so prices are unlikely to drop in the short term, which also means patients or families need to bear a higher financial burden.

Overall, the accessibility of vosolitide in China is still limited, it is not covered by medical insurance, and the cost is relatively high. Patients and family members should learn about overseas drug purchase and clinical trial information through formal medical consultation, and pay attention to the approval and marketing of drugs in China. As drugs are gradually approved for marketing, more formal drug purchase channels and medical insurance support may appear in the future, thereby improving accessibility and treatment feasibility for children.

Reference materials:https://www.drugs.com/